IMRA - IMRA STOCK NEWS

Enliven Therapeutics and Imara have announced a merger agreement to combine their operations in an all-stock transaction. The new entity will focus on advancing Enliven’s precision oncology programs, notably ELVN-001 and ELVN-002. The merger will result in a cash balance of approximately $300 million to support clinical milestones through early 2026. A concurrent financing of $165 million is also planned, co-led by major investors. The merger is subject to stockholder approval and expected to close in Q1 2023, with Enliven becoming the new name under the ticker ELVN.

Imara announced disappointing interim results from its Phase 2b Ardent trial for sickle cell disease and Forte trial for beta-thalassemia, leading to the discontinuation of both studies. The Ardent trial showed no significant differences in the median annualized rate of vaso-occlusive crises between the high-dose tovinontrine group and placebo. The Forte trial reported no meaningful benefit in transfusion burden or disease biomarkers. Despite the findings, tovinontrine was generally well-tolerated. Imara is now exploring new strategic options, including potential development in heart failure with preserved ejection fraction.

Imara Inc. (Nasdaq: IMRA) announced the completion of enrollment in Phase 2b trials for sickle cell disease and beta-thalassemia with tovinontrine (IMR-687), expecting interim datasets in early April 2022. The FDA requested a change in the primary endpoint of the Ardent trial to annualized rate of VOCs. Additionally, tovinontrine's clinical indication was expanded to treat heart failure with preserved ejection fraction (HFpEF), with initial dosing anticipated in Q2 2022. The pipeline now includes IMR-261, a novel Nrf2 activator.

Imara Inc. (Nasdaq: IMRA) will host a conference call and live webcast on March 15, 2022, at 8:30 a.m. ET to discuss its financial results for 2021 and recent business highlights. The call will provide insights into the company's progress in developing therapeutics for rare hemoglobin disorders and other serious diseases. Notably, Imara is advancing tovinontrine (IMR-687) in Phase 2b trials for sickle cell disease and beta-thalassemia, and plans to initiate a Phase 2 trial of the drug in heart failure by Q2 2022.

Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical firm, announced participation in the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022. CEO Rahul Ballal, Ph.D., will partake in a Fireside Chat at 3:40 p.m. ET, focusing on the company’s advancements in rare hemoglobin disorders. Imara is progressing with tovinontrine (IMR-687), a treatment for sickle cell disease and beta-thalassemia in Phase 2b trials, and plans to initiate another trial in heart failure (HFpEF) by Q2 2022. Further details available on Imara’s website.

Imara Inc. (Nasdaq: IMRA) has received FDA approval for its investigational new drug application for tovinontrine (IMR-687) targeting heart failure with preserved ejection fraction (HFpEF). A Phase 2 trial, set to begin in Q2 2022, will evaluate its efficacy in patients aged 45 and older with persistent HFpEF symptoms and high PDE9 expression. The trial will involve 170 patients and assess primary endpoints such as NT-proBNP changes. The therapy aims to enhance cGMP levels, potentially improving symptoms in patients with coexisting hemoglobin disorders.

Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company, will be presenting at the H.C. Wainwright BioConnect 2022 Virtual Conference from January 10-13, 2022. The pre-recorded presentation will be available on January 10 at 7:00 AM ET on their website. Imara is focused on developing therapeutics for rare genetic disorders, advancing tovinontrine (IMR-687) for sickle cell disease and beta-thalassemia, and IMR-261 as an Nrf2 activator.

Imara Inc. presents data on IMR-261, a novel Nrf2 activator, at the ASH Annual Meeting, demonstrating its potential in treating sickle cell disease (SCD) and beta-thalassemia. In preclinical studies, high doses showed a 7-fold increase in fetal hemoglobin (HbF) and an approximately 3-fold increase in F-cells compared to placebo. Additionally, IMR-261 decreased markers of hemolysis and reduced vaso-occlusive crises (VOCs). The company seeks to further explore IMR-261’s applications beyond hemoglobin disorders, indicating robust preclinical data and promising next steps for development.

Imara Inc. (Nasdaq: IMRA) released positive 12-month data from its Phase 2a open-label extension trial for tovinontrine in treating sickle cell disease (SCD). The trial demonstrated a 38% reduction in the annualized rate of vaso-occlusive crises (VOCs) among patients, with stable rates reported during treatment. Tovinontrine was well-tolerated, with no significant adverse events. Additionally, preclinical data highlighted its effectiveness in beta-thalassemia. The company anticipates initial VOC data from its Ardent Phase 2b trial in Q1 2022.